New drug combo trial offers hope for tough stomach cancers
NCT ID NCT05671822
Summary
This study is testing a new drug called SHR-A1811, given with chemotherapy and/or immunotherapy, for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The first part checks the safety and best dose of the combinations. The second part measures how well the treatments work to shrink tumors and control the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 EXPRESSION GASTRIC CANCER/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital, FuDan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact
Conditions
Explore the condition pages connected to this study.